Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I would like to get a whole lotta love after hours with an announcement.
getting some love today (must be valentines day)
great read here, probably jump started us today....
http://www.dailyfinance.com/story/stock-picks/two-reasons-for-clinical-data-shares-to-soar/19842051/
looks like we got a spark kids.....
Got a run going
either news has leaked about a buyout
orn the shorts are getting nailed or both !!!!
Good post
I saw that
has real meaning !!
Clda post.....
On the yahoo board from a woman who said she got a package over the weekend from Schwabb saying they would like to pay her 3% a month to lend her 5k shares out, apparently Schwabb is trying to find shares because the lack of with all the short positions
Check it out for details...
Oh baby this week should be interesting, long and strong...
Stay cool.....
LCK
Well the dilution took its big ZIOP dip now Fidelity and Kirk along with a few others own a ton..so do I
I bought too!!
CLDA is really holding well pending the news to come.
ZIOP will probably leap back to 6+ after CLDA deal consumated !!
I HAVE NO DOUBT THAT THE COMPANY IS IN PLAY AND THAT THEY ARE IN A "QUIET PERIOD". THEY WILL NEVER GET ANY INFO FROM CLDA INVESTORS. THEY ARE ALWAYS LOCKED DOWN.
ALL THIS FALSE BRAVADO REGARDING GOING IT ALONE BY RJ IS JUST PLAIN GOOD NEGOTIATING. OF COURSE HE IS CAPABLE OF DOING IT BUT IF THE PRICE IS RIGHT HE WOULD PREFER TO MOVE ON WITH ZIOP.
I AM CERTAIN THAT PUTTING A VALUE ON STEDIVAZE STILL IN TRIAL IS SLOWING THE PROCESS. V DRUG VALUE IS OBVIOUS.
I AGREE , LIKELY TO GET IT DONE OVER THE WEEKEND IMHO.
Something is brewing
But mums the word, she said that in the cc Kirk had mentioned they would not give updates on this.
All I know is another day, no secondary....not concerned about the price action today, I realize it's being played with by shorts and such just like prior to approval....some cat on the yahoo board say his "sources" tell him that there is 3 players in this and news will come AH tomorrow or Monday....
Gotta love it......bottom line is when it happens, it happens....glad I'm in this and ZIOP
Stay cool Autosinger
Sounds like something may be going on if she can't discuss it.
what's happening everyone?
emailed corporate today just for my own peace of mind....Theresa said she couldn't discuss
if the "change of control" discussions we're still going on...thought I would atleast give it a shot
I still think its holding the upper 20's nicely
stay cool
Me too, one of the best!
I ENJOY THE GUY ON YAHOO THAT LAUGHS AT THE BASHERS
IF IT DROPS TO 27.50 i AM BUYING
SHORTS ARE KILLING US RIGHT NOW BUT REMEMBER ,, KARMA
I think the yahoo board will make a person nervous, that's what happened to me the other day. The nay-sayers can spin any news into something negative. Most of them seem to come out after lunch and may be just one or two people. Although we don't have a buyout yet, we don't have a secondary either, which is good news the way I see it. I still think that Kirk is trying to negotiate the best possible deal for us and that he is not going to give the company away just to move on to his new venture.
Question for Gator........
As always I do my own DD and feel comfortable with it....
You have been following CLDA for awhile and if you see something you DON'T like, or questionable would you mind posting it? As brothers and sisters we can help each other out.....
Best wishes and appreciation......
LCK
How are we doing here?
Felt a tad bit nervous today, probably reading to much on the yahoo message board.....man they are getting really negative
Still feeling Kirk is gonna move this thing, just found myself second guessing today
Anyhow holding a bunch at 15 and the same at 29.50......comfortable with my position
Good! I have been adding and am ready!
I THINK THE ANALYSTS AND MM'S ARE ABOUT TO DO THEIR MAGIC AND RUN THIS UP TO $7 JUST A GOOD HUNCH
Wed Feb 9 2011 8:45:48 AM EST Kirk already involved !!
BusinessWire, GlobeNewswire and PR Newswire News
ZIOPHARM Oncology Inc ZIOP:NASDAQ
Intrexon Appoints Vice President of Alliance Management for Human Therapeutics
BusinessWire
8:45 AM ET
Intrexon Corporation, a next generation synthetic biology company, today announced the appointment of Cary P. Moxham, Ph.D., as VP of Alliance Management for its Human Therapeutics alliances. Dr. Moxham's leadership activities will be focused, first and foremost, on Intrexon's exclusive channel partnership with ZIOPHARM Oncology, Inc., which was announced on January 6, 2011.
Dr. Moxham was most recently Senior Director, Alliance Management at Gilead Sciences, Inc., a role in which he served as the primary contact with multiple partner companies. During this lengthy tenure, Dr. Moxham led the management of governance committees and working group meetings to maximize adherence with established time lines and deliverables, including liaising with Legal, IP, Finance, R&D, and Commercial personnel. Prior to serving in Alliance Management, Dr. Moxham was Senior Director of Clinical Research at Gilead where he managed the Clinical Operations group based in Durham, NC responsible for execution of development programs in HIV and HBV. Dr. Moxham received his Ph.D. in Biochemical Pharmacology at State University of New York at Stony Brook, and a Bachelors of Science in Biology and Chemistry at Union College in Schenectady. His post-doctoral fellowship and subsequent project leadership at Burroughs Wellcome, Co./Glaxo Wellcome, Inc., led to recruitment by Triangle Pharmaceuticals, Inc., where he held leadership and management roles within Clinical Research and Business Development/Operations. Dr. Moxham served as the primary contact for R&D information in support of du e diligence preceding Gilead's acquisition of Triangle in 2003. Dr. Moxham is an accomplished clinical R&D scientist with numerous peer-reviewed publications and manuscripts.
"I became very intrigued with Intrexon after being introduced to the company's ability to induce and regulate in vivo protein expression through the dosing of a small molecule activator," states Dr. Moxham. "The novel therapeutic platform Intrexon has developed has the potential to solve a number of safety and efficacy challenges that have confronted the clinical production and dosing of recombinant therapeutic proteins. I am very excited to be a part of helping Intrexon and its channel partners harness the full potential of this industry-sh aping platform and realize the downstream commercial success of many high value therapeutics."
Randal J. Kirk, Intrexon's Chairman and CEO, comments, "I am very pleased we have an alliance executive with the experience and capabilities of Dr. Moxham managing our human therapeutics channel partnerships. He is already engaged on our new ZIOPHARM partnership and working closely with the joint committees on the planning and execution of our global alliance in oncology. I welcome him to the Intrexon team and look forward to the results of his leadership."
About Intrexon Corporation
Intrexon Corporation is a privately held synthetic biology company that employs modular DNA control systems to enhance capabilities, improve safety and lower cost in human therapeutics, protein production, industrial products and agricultural biotechnology. The company's advanced transgene engineering platform enables Better DNA(TM) by combining breakthroughs in DNA control systems with corresponding advancements in modular transgene design, assembly and optimization. The company is currently using these advanced capabilities to undertake foremost challenges across the spectrum for biological applications. More information about the company is available at www.DNA.com.
SOURCE: Intrexon Corporation Kirk already involved
Intrexon Corporation Robert Beech, 301-556-9812 rbeech@intrexon.com
Business Wire is a registered trademark of Business Wire. GlobeNewswire is a registered trademark of The NASDAQ OMX Group, Inc. PR Newswire is a registered trademark of PR Newswire Association, Inc.
Please do not reply to this e-mail from Wall Street on Demand. Wall Street on Demand and TD Ameritrade are separate unaffiliated companies and are not responsible for each other's service. For questions regarding your brokerage account, please contact TD Ameritrade Client Services at 1-800-669-3900.
To stop receiving this alert from TD Ameritrade, please click here to update your subscription settings. You may also unsubscribe from all of your alerts using the link above. As always, you can manage all of your alert settings by logging into your TD Ameritrade account and navigating to Research & Ideas > Alerts.
I don't think so Mr.Dew.
Yesterday morning things dropped a little too quickly. I feel much better after today. Thanks!
no reason to be nervous at all
We won't need samples if it goes to 40! haha
PFE buyout rumor started on cafepharma
Do we all get free samples of V when this is over? We could use it.....lol
I agree. I am trying.
What a ride.....here is a nice pop
DJ issued a buy rating on ZIOP today.......target 8$....link on ZIOP board
Everyone is looking north......
Great time to work on being patient and calm for me
I sure wish the company would make some sort of positive announcement. This is becoming a sell off.
Nervous Nellie
ziop
Tue Feb 8 2011 6:35:28 AM EST
BusinessWire, GlobeNewswire and PR Newswire News
ZIOPHARM Oncology Inc ZIOP:NASDAQ
ZIOPHARM to Present at the 13th Annual BIO CEO & Investor Conference
BusinessWire
6:35 AM ET
ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), announced today that Jonathan Lewis, M.D., Ph.D., Chief Executive Officer, will present at the 13th Annual BIO CEO & Investor Conference on Tuesday, February 15, 2011 at 2:00 pm Eastern Time at the Waldorf=Astoria Hotel in New York City. Dr. Lewis will provide an overview of the Company and its clinical development programs.
To access a live webcast of the presentation, please visit the Investor Relations section at www.ziopharm.com. The webcast will be archived for ninety days.
Ab out ZIOPHARM Oncology, Inc.:
ZIOPHARM Oncology is a biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of cancer drugs. The Company is currently focused on three clinical programs.
Palifosfamide (ZymafosTM or ZIO-201) is a novel DNA cross-linker in class with bendamustine, ifosfamide, and cyclophosphamide. ZIOPHARM is currently enrolling patients in a randomized, double-blinded, placebo-controlled Phase III trial with palifosfamide administered intravenously for the treatment of metastatic soft tissue sarco ma in the front-line setting. The Company is also currently conducting a Phase I intravenous study of palifosfamide in combination with standard of care addressing small cell lung cancer and expects to initiate an additional study with drug in the oral form treating solid tumors.
Darinaparsin (ZinaparTM or ZIO-101) is a novel mitochondrial-targeted agent (organic arsenic) being developed intravenously for the treatment of peripheral T-cell lymphoma with a pivotal study expected to begin in late 2011. An oral form is in a Phase I trial in solid tumors.
Indibulin (ZybulinTM or ZIO-301) is a novel, oral tubulin binding agent that is expected to have several potential benefits including oral dosing, application in multi-drug resistant tumors, no neuropathy and minimal overall toxicity. It is currently being studied in Phase I/II in metastatic breast cancer.
ZIOPHARM is also pursuing the development of novel DNA-based therapeutics in the field of cancer pursuant to a partnering arrangement with Intrexon Corporation. The partnership includes two existing clinical-stage product candidates, the first of which is in a Phase Ib study and the second of which is the basis of an Investigational New Drug application that ZIOPHARM expects to submit during the first half of 2011.
ZIOPHARM's operations are located in Boston, MA with an executive office in New York City. Further information about ZIOPHARM may be found at www.ziopharm.com.
ZIOP-G
Forward-Looking Safe Harbor Statement:
This press release contains forward-looking statements for ZIOPHARM Oncology, Inc. that involve risks and uncertainties that could cause ZIOPHARM Oncology's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurance that any of ZIOPHARM Oncology's development efforts relating to its product candidates will be successful, or such product candidates will be successfully commercialized. Other risks that affect forward-looking information contained in this press release include the possibility of being unable to obtain regulatory approval of ZIOPHARM Oncolo gy's product candidates, the risk that the results of clinical trials may not support ZIOPHARM Oncology's claims, the risk that pre-clinical or clinical trials will proceed on schedules that are consistent with ZIOPHARM Oncology's current expectations or at all, risks related to ZIOPHARM Oncology's ability to protect its intellectual property and its reliance on third parties to develop its product candidates, risks related to the sufficiency of existing capital reserves to fund continued operations for a particular amount of time and uncertainties regarding ZIOPHARM Oncology's ability to obtain additional financing to support its operations thereafter, as well as other risks regarding ZIOPHARM Oncology's that are discussed under the heading "Risk Factors" in ZIOPHARM Oncology's filings with the United States Securities and Exchange Commission. Forward-looking statements c an be identified by the use of words such as "may," "will," "intend," " should," "could," "can," "would," "expect," "believe," "estimate," " predict," "potential," "plan," "is designed to," "target" and similar expressions. ZIOPHARM Oncology assumes no obligation to update these forward-looking statements, except as required by law.
SOURCE: ZIOPHARM Oncology, Inc.
ZIOPHARM Oncology, Inc. Tyler Cook, 617-259-1982 tcook@ziopharm.com or Media: Argot Partners David Pitts, 212-600-1902 david@argotpartners.com
Business Wire is a registered trademark of Business Wire. GlobeNewswire is a registered trademark of The NASDAQ OMX Group, Inc. PR Newswire is a registered trademark of PR Newswire Association, Inc.
Please do not reply to this e-mail from Wall Street on Demand. Wall Street on Demand and TD Ameritrade are separate unaffiliated companies and are not responsible for each other's service. For questions regarding your brokerage account, please contact TD Ameritrade Client Services at 1-800-669-3900.
To stop receiving this alert from TD Ameritrade, please click here to update your subscription settings. You may also unsubscribe from all of your alerts using the link above. As always, you can manage all of your alert settings by logging into your TD Ameritrade account and navigating to Research & Ideas > Alerts.
you did well
relax and enjoy.
I loaded@ 29.50 before the close
My 28.50 didn't get filled
Thx for the positivity!
Blessings.....
No doubt in my mind especially after the huge ZIOP play by Kirk
He is ready for the next challenge
No I am not the Kirk
I loaded under 30 today
anything under 32 is still a safe buy IMHO
Hey Gator are you...........
Captain_rj_Kirk on the yahoo board?
Do you suggest loading more under 30?
Do you still think CLDA is going to get bought out? I do.
MORE DILUTION
Kirk just bought 1,910,000 more ZIOP shrs-Form 4 just hit 5 minutes ago
Kirk just bought 1,910,000 more ZIOP shrs-Form 4 just hit
I predicted this on the ZIOP board this morning - bought Friday dip.
ZIOP is going higher
GUIDED BY THE HOLY SPIRIT MY BROTHER
LOTS AND LOTS OF PARAYER AND THANKS
AND TITHING
missed the 28.50!
going back in.......
Gator your a baller!
IMHO BUY A LOT AND WAIT
another 1000 at 29.12
picked up 2000 at an ave of 30.12 this AM
Motley is crap
They didnt get the name "fools" for no reason :p
Yea when Motley blogs I do the opposite and it seems to work out
Followers
|
4
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
903
|
Created
|
07/17/06
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |